Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACE-trial: Neoadjuvant Radiochemotherapy Versus Chemotherapy for GEJ Adenocarcinoma
NCT04375605Phase 3Completed
- Sponsor
- Universitätsmedizin Mannheim
- Start
- Jun 2020
- Primary completion
- Jun 2026
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, folinic acid, oxaliplatin and docetaxel in adenocarcinoma of the gastroesophageal junction (2 arms), sponsored by Universitätsmedizin Mannheim. Primary endpoint: Progression-Free Survival at 5 years. Started Jun 2020; status: completed.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxel
03
Conditions
adenocarcinoma of the gastroesophageal junction
Beyond the preview
Go deeper on NCT04375605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375605.